Clinuvel Pharmaceuticals Limited Stock Nasdaq
Stocks
CUVL
US1887691038
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Nasdaq
16:30:00 2026-08-27 EDT
|
5-day change | 1st Jan Change | ||
| 6.770 USD | -11.44% |
|
-13.21% | -20.17% |
| Market Cap | 463M 333M 286M 268M 245M 462M 31.8B 3.17B 1.24B 16.03B 1.25B 1.22B 53.05B | P/E 2027 * |
14.9x | P/E 2028 * | 9.82x |
|---|---|---|---|---|---|
| Enterprise Value | 186M 134M 115M 107M 98.42M 185M 12.77B 1.27B 498M 6.44B 502M 491M 21.31B | EV / Sales 2027 * |
2.01x | EV / Sales 2028 * | 1.18x |
| Free-Float |
83.79% | Yield 2027 * |
0.71% | Yield 2028 * | 1.02% |
Last Transcript : Clinuvel Pharmaceuticals Limited
| 1 day | -11.44% | ||
| 1 week | -13.21% | ||
| Current month | +4.31% | ||
| 1 month | -3.42% | ||
| 3 months | +3.20% | ||
| 6 months | -10.45% | ||
| Current year | -20.17% |
| 1 week | 6.76 |  | 8.2 |
| 1 month | 6.2 | | 8.2 |
| Current year | 5.98 | | 8.67 |
| 1 year | 5.98 | | 8.92 |
| 3 years | 5.98 | | 13.45 |
| 5 years | 5.98 | | 31.44 |
| 10 years | 3.81 | | 31.44 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 2005-10-31 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 2024-06-29 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 2018-01-28 |
Susan Smith
BRD | Director/Board Member | - | 2019-09-22 |
| Chairman | - | 2023-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -11.44% | -13.21% | - | - | 380M | |
| -0.87% | -2.29% | +37.61% | -2.73% | 81.36B | |
| -4.60% | +7.09% | +468.80% | +27.55% | 59.75B | |
| -1.09% | +3.29% | -20.08% | -35.82% | 59.19B | |
| +0.76% | +3.53% | +0.08% | +36.18% | 53.33B | |
| +0.41% | +1.84% | +10.29% | +171.67% | 49.09B | |
| +0.19% | +3.34% | +62.44% | -16.23% | 32.66B | |
| -0.30% | +0.41% | +50.57% | +100.03% | 25.97B | |
| 0.00% | +5.08% | +18.70% | +209.64% | 24.39B | |
| +0.78% | +0.47% | +61.53% | +123.40% | 16.91B | |
| Average | -1.20% | +2.73% | +76.66% | +68.19% | 44.74B | |
| Weighted average by Cap. | -0.24% | +2.40% | +87.52% | +47.01% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 92.55M 66.57M 57.15M 53.5M 48.99M 92.29M 6.36B 634M 248M 3.2B 250M 245M 10.61B | 124M 89.17M 76.55M 71.66M 65.62M 124M 8.52B 849M 332M 4.29B 335M 328M 14.21B |
| Net income | 31.4M 22.59M 19.39M 18.15M 16.62M 31.31M 2.16B 215M 84.02M 1.09B 84.8M 82.97M 3.6B | 47.18M 33.94M 29.13M 27.28M 24.98M 47.05M 3.24B 323M 126M 1.63B 127M 125M 5.41B |
| Net Debt | -277M -199M -171M -160M -147M -276M -19.03B -1.9B -741M -9.59B -748M -732M -31.74B | -316M -228M -195M -183M -167M -315M -21.73B -2.17B -847M -10.95B -854M -836M -36.25B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-27 | US$6.770 | -11.44% | 30,794 |
| 26-08-26 | US$7.644 | +0.58% | 1,339 |
| 26-08-25 | US$7.600 | +2.43% | 14,095 |
| 26-08-24 | US$7.420 | -4.87% | 26,659 |
| 26-08-20 | US$7.800 | +9.09% | 26,407 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
- CUVL Stock
Select your edition
All financial news and data tailored to specific country editions
